Found 285 articles for: "biologics"
Dermatologists' Perspectives on Biosimilars
April 2024 | Volume 23 | Issue 4 | Features | 277 | Copyright © April 2024
Background: Biosimilars are biologic agents the Food and Drug Administration (FDA) has deemed to have no clinical difference from their reference biologics. In dermatology, biosi...
Read MoreFirst Use of Combination Oral Deucravacitinib With Tapinarof Cream for Treatment of Severe Plaque Psoriasis
March 2024 | Volume 23 | Issue 3 | Case Reports | 192 | Copyright © March 2024
Plaque psoriasis is a chronic, immune-mediated, cutaneous, and systemic inflammatory dermatosis. Its pathogenesis involves the dysregulation of the interleukin (IL)-23/IL-17 signaling pathway. Th...
Read MoreOutcomes for Psoriasis by Self-Identified Racial Groups in Ixekizumab Clinical Trials: A Pooled Analysis
February 2024 | Volume 23 | Issue 2 | Original Article | 17 | Copyright © February 2024
Background: Biologics have shown promising outcomes in psoriasis clinical trials. However, there is a paucity of data exploring the potential differences in outcomes between self...
Read MoreA New Tool to Improve Communication Between Hidradenitis Suppurativa Patients and Health Care Providers
February 2024 | Volume 23 | Issue 2 | Features | 105 | Copyright © February 2024
Background: Hidradenitis suppurativa (HS) patients tend to experience diagnosis delay, misdiagnosis, and embarrassment due to their condition. To address these issues, the Intern...
Read MoreImplicit Bias and Clinical Decision Making in Psoriasis Management Among Dermatology Residents: A Feasibility Study
February 2024 | Volume 23 | Issue 2 | Editorials | e73 | Copyright © February 2024
Psoriasis and Palmoplantar Pustulosis Following Pembrolizumab Therapy Successfully Treated With Topical Tapinarof Cream 1%
February 2024 | Volume 23 | Issue 2 | Case Reports | 103 | Copyright © February 2024
Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis
February 2024 | Volume 23 | Issue 2 | Original Article | 74 | Copyright © February 2024
Early response to treatment with biologics, defined as Psoriasis Area and Severity Index (PASI) of 2 or less six months after initiation of therapy, seems to be associated with more stable psoria...
Read MoreTargeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis
February 2024 | Volume 23 | Issue 2 | Original Article | 23 | Copyright © February 2024
Atopic dermatitis (AD) is a chronic relapsing–remitting disease with a multifactorial etiology involving epidermal barrier and immunologic dysfunction. Topical therapies form the mainstay o...
Read MoreAtopic Dermatitis as a Paradoxical Reaction to Secukinumab in a Patient With Plaque Psoriasis
February 2024 | Volume 23 | Issue 2 | Case Reports | 97 | Copyright © February 2024
Paradoxical reactions to biologic agents used in the treatment of psoriasis are rare but have been reported with tumor necrosis factor (TNF) blockers and, more recently, with interleukin (IL)-17A...
Read MoreA Case Series of TNF Inhibitor-Induced Psoriasis Successfully Treated With Upadacitinib
February 2024 | Volume 23 | Issue 2 | Case Reports | e60 | Copyright © February 2024
Tumor necrosis factor-alpha inhibitors (TNF-i) are commonly used to treat immune-mediated diseases such as psoriasis, psoriatic arthritis (PsA), inflammatory bowel disease (IBD), spondyloarthriti...
Read MoreFactors Impacting New Drug Adoption in the Clinical Setting: A Survey of Dermatologists
January 2024 | Volume 23 | Issue 1 | Editorials | 1362 | Copyright © January 2024
A Case Series of Patients With Eczematous Eruptions Following IL-17 Inhibitor Treatment for Psoriasis Vulgaris
December 2023 | Volume 22 | Issue 12 | Case Reports | 1225 | Copyright © December 2023
Psoriasis vulgaris and eczema are characterized by an imbalance in the Th1 and Th2 immune response and distinct cytokine profiles, where Th1 is more prominent in psoriasis and Th2 is more promine...
Read MoreOff-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases
December 2023 | Volume 22 | Issue 12 | Original Article | 1183 | Copyright © December 2023
Dysregulation of Janus kinase (JAK) pathways from uncontrolled cytokine signaling comprises the pathological basis for many complex inflammatory cutaneous disorders. Oral JAK inhibitors, upadacit...
Read MoreINDIVIDUAL ARTICLE: Management of Prurigo Nodularis
December 2023 | Volume 22 | Issue 12 | Supplement Individual Articles | SF365502s15 | Copyright © December 2023
Background: Prurigo nodularis (PN) is a chronic disease characterized by intense pruritus and nodular lesions associated with reduced quality of life. Until recently, no US Food ...
Read MorePrior Authorization Timeliness and Success At a Single Center Centralized Pharmacy
December 2023 | Volume 22 | Issue 12 | Editorials | 1233 | Copyright © December 2023
INDIVIDUAL ARTICLE: USCOM Algorithm for the Prevention and Management of Cutaneous Immunotherapy-Related Adverse Events
November 2023 | Volume 22 | Issue 11 | Supplement Individual Articles | SF389716s4 | Copyright © November 2023
Background: In 2023, nearly 2 million patients will be diagnosed with cancer in the United States and at least 40% will be eligible for treatment with an immune checkpoint inhibi...
Read MoreINDIVIDUAL ARTICLE: Real-World Evidence on the Use of Calcipotriene and Betamethasone Dipropionate Aerosol Foam 0.005%/0.064% in the Treatment of Psoriasis: A Review of Investigator-Initiated Studies Around the Globe
September 2023 | Volume 22 | Issue 9 | Supplement Individual Articles | SF378719s5 | Copyright © September 2023
Topical medications are commonly used to manage mild-to-moderate psoriasis and serve as adjunct therapies used in combination with phototherapy and systemic treatments. Fixed-dose calcipotriene (Cal) ...
Read MoreDapsone to Treat Moderate-to-Severe Hidradenitis Suppurativa: A Retrospective Case-Series
November 2023 | Volume 22 | Issue 11 | Features | e12 | Copyright © November 2023
Background: Management of hidradenitis suppurativa (HS) is challenging since no single treatment provides consistently effective results, leaving patients with frequent relapses....
Read MoreFULL SUPPLEMENT: Brodalumab: Five Years of Real-World Safety and Efficiency
October 2023 | Volume 22 | Issue 10 | Department | SF378632s1 | Copyright © October 2023
Psoriasis remains a highly prevalent condition in the United States and worldwide. Preclinical research has been triumphant in elucidating the critical immunological pathways involved in psoriasi...
Read MoreIndividual Article: Brodalumab Is an Efficacious, Safe, and Cost-Effective IL-17 Receptor Blocker for the Treatment of Moderate-to-Severe Plaque Psoriasis: 2023 Update
October 2023 | Volume 22 | Issue 10 | Supplement Individual Articles | SF378632s5 | Copyright © October 2023
Media and other results for: "biologics"
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
